Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $32 and keeps a Sell rating on the shares. The firm updated the company’s model following the recent closure of the deal with Novartis for PTC518 as well as recent pipeline updates. However, Citi believes PTC’s upcoming catalysts have some risk.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald
- PTC Therapeutics price target raised to $50 from $46 at TD Cowen
- PTC Therapeutics price target lowered at Cantor Fitzgerald, a top pick in 2025
- PTC Therapeutics Surpasses Revenue Guidance for 2024
- PTC Therapeutics provides potential key clinical, regulatory events in 2025